Pharmacogenomics Market Size (2024 - 2029)

The pharmacogenomics market is projected to experience significant growth, driven by the increasing emphasis on precision medicine and heightened research and development expenditures. This market expansion is fueled by the rising adoption of pharmacogenomics technologies, which aim to tailor treatments based on genetic and environmental factors, thereby reducing adverse drug reactions. The integration of advanced digital technologies and biological advancements further supports this growth. However, challenges such as reimbursement issues and difficulties in detecting gene variations that influence drug responses may pose constraints on the market's expansion.

Market Size of Pharmacogenomics Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Pharmacogenomics Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 8.67 Billion
Market Size (2029) USD 11.67 Billion
CAGR (2024 - 2029) 6.12 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Pharmacogenomics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Pharmacogenomics Market Analysis

The Pharmacogenomics Market size is estimated at USD 8.67 billion in 2024, and is expected to reach USD 11.67 billion by 2029, growing at a CAGR of 6.12% during the forecast period (2024-2029).

The pharmacogenomics market is driven by the rising popularity of precision medicine, coupled with growing research and development expenditures on pharmacogenomics technologies, which is accelerating the development of novel products. The high incidence rate of adverse drug reactions is also driving the higher adoption of pharmacogenomics in the global market.

The increasing focus on precision medicine is expected to augment the pharmacogenomics market, as the precision medicine approach aims to integrate genetic and environmental information about diseases and their responses to treatments. For instance, in June 2023, the National Cancer Institute introduced a precision medicine initiative known as Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH), which can evaluate the different drug combinations for cancer patients based on tumor biology. With the rapid growth in digital technologies and advances in biology, the pharmacogenomics market is projected to grow significantly.

Additionally, increasing research and development spending is contributing to the adoption of pharmacogenomics and driving the market's growth. For instance, in March 2023, Allroion Therapeutics, the next-generation precision medicine company focusing on oncology and autoimmune disorders, completed a USD 50 million Series B financing round to develop upcoming clinical trials in phase I/II in China and the United States. This increase in R&D spending is expected to boost the market’s growth during the forecast period.

Sanger technology and next-generation sequencing are increasingly adopted in academic and institutional research projects. Additionally, a rise in funding and investment programs augment these entities' demand for DNA sequencing products. For instance, in January 2024, according to the National Cancer Institute, the spending on cancer research funding increased significantly from USD 6.72 billion in 2022 to USD 7.10 billion in 2023 in the United States. This data shows significant investment in genomics and personalized medicine, which is expected to impact the pharmacogenomics market's growth positively. Pharmacogenomics is also helpful in cancer treatment and has proved to improve the survival of patients. At the same time, it has also been found to reduce the unnecessary cost of unresponsive therapy by patients.

Therefore, factors such as increasing focus on precision medicine and growing research and development spending are expected to enhance the growth of the pharmacogenomics market during the forecast period. However, issues related to reimbursement and problems associated with the detection of gene variation that affects drug response may restrain the growth of the pharmacogenomics market during the forecast period.

Pharmacogenomics Industry Overview

As per the scope of this report, pharmacogenomics provides accurate insights into making clinical decisions and determining the most effective treatment by varying the dosages of drugs. The field of pharmacogenomics is predicted to treat a wide range of health problems, including cardiovascular diseases, Alzheimer's disease, cancer, HIV/AIDS, and asthma. The pharmacogenomics market is segmented by technology, application, and geography. By technology, the market is segmented into DNA sequencing, microarray, polymerase chain reaction, electrophoresis, mass spectrometry, and other technologies. By application, the market is segmented into drug discovery, neurology, oncology, pain management, and other applications. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. For each segment, the market size is provided in terms of value (USD).

By Technology
DNA Sequencing
Microarray
Polymerase Chain Reaction
Electrophoresis
Mass Spectrometry
Other Technologies
By Application
Drug Discovery
Neurology
Oncology
Pain Management
Other Applications
By Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Pharmacogenomics Market Size Summary

The pharmacogenomics market is poised for significant growth, driven by the increasing emphasis on precision medicine and substantial investments in research and development. The market is experiencing a surge in interest due to its potential to enhance drug efficacy and minimize adverse drug reactions by tailoring treatments based on genetic and environmental factors. This approach is gaining traction as it aligns with the broader trend towards personalized medicine, which aims to optimize therapeutic outcomes by considering individual genetic profiles. The market's expansion is further supported by advancements in digital technologies and biological research, which are facilitating the development of innovative pharmacogenomics products. However, challenges such as reimbursement issues and the complexities of detecting gene variations that influence drug responses may pose obstacles to market growth.

North America is expected to dominate the pharmacogenomics market, bolstered by robust healthcare infrastructure, high investment in personalized medicine, and a significant prevalence of chronic diseases. The region's growth is further enhanced by the presence of numerous research institutions focused on developing novel therapeutics and the introduction of new products and services that improve access to pharmacogenomics testing. The market is characterized by intense competition, with numerous key players and government support for bioinformatics technology development. As the demand for advanced therapeutics continues to rise, the pharmacogenomics market is anticipated to expand, with North America, particularly the United States, leading the charge during the forecast period.

Explore More

Pharmacogenomics Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Focus on Precision Medicine

      2. 1.2.2 Increasing Expenditure in Research and Development

      3. 1.2.3 High Rate of Adverse Drug Reaction

      4. 1.2.4 Enhancement of Drug Safety and Efficiency to Increase Success Rates in Pharmaceutical R&D

    3. 1.3 Market Restraints

      1. 1.3.1 Difficulties in Detecting Gene Variation that Affect Drug Response

      2. 1.3.2 Reimbursement Issues

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 2.1 By Technology

      1. 2.1.1 DNA Sequencing

      2. 2.1.2 Microarray

      3. 2.1.3 Polymerase Chain Reaction

      4. 2.1.4 Electrophoresis

      5. 2.1.5 Mass Spectrometry

      6. 2.1.6 Other Technologies

    2. 2.2 By Application

      1. 2.2.1 Drug Discovery

      2. 2.2.2 Neurology

      3. 2.2.3 Oncology

      4. 2.2.4 Pain Management

      5. 2.2.5 Other Applications

    3. 2.3 By Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Pharmacogenomics Market Size FAQs

The Pharmacogenomics Market size is expected to reach USD 8.67 billion in 2024 and grow at a CAGR of 6.12% to reach USD 11.67 billion by 2029.

In 2024, the Pharmacogenomics Market size is expected to reach USD 8.67 billion.

Pharmacogenomics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)